

(NIH/NIAID) [E] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6)>;  
Harper, Jill (NIH/NIAID) [E] (b) (6)>  
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E]  
<(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston,  
Hilary (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E]  
(b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon  
(NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)  
Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6)>;  
Lee, Kun-Lin (NIH/NIAID) [E] <(b) (6)>; Bushar, Nicholas (NIH/NIAID) [E]  
(b) (6)>; Schneider, Johanna (NIH/NIAID) [E] (b) (6)>

**Subject:** RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/17/20

Tony,

YTD spending is \$78.4M, an increase of \$10.9M from last week including costs to evaluate therapeutics in humans and NHPs, manufacture of a prototype virus-like vaccine candidate developed by Taubenberger/Memoli, and spending to accelerate discovery of new therapeutics , vaccines and diagnostics.

(b) (5)

Martin